Does HYFT pay dividends?

ImmunoPrecise Antibodies Ltd. (HYFT) does not currently pay a regular dividend.

What is HYFT's market cap?

ImmunoPrecise Antibodies Ltd. (HYFT) has a market capitalization of $62.96M with a current stock price of $1.34.

ImmunoPrecise Antibodies Ltd. (HYFT)

Official site

HEALTHCARE • NONE • NASDAQ

$1.34

-0.05 (-3.60%)

Market Cap: $62.96M

Last updated: Sep 01, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

31%(4/13)

Avg Surprise

-98.57%

Upcoming Estimates

Period ending Jul 31, 2026

EPS Consensus$-0.05

Range$-0.06 - $-0.05

3 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate Drift

90d ago$-0.05+13.2%

60d ago$-0.05+13.2%

30d ago$-0.05+13.2%

7d ago$-0.05+13.2%

Current$-0.05

Revenue Consensus

$5M

Range$4M - $5M

3 analysts

Period ending Oct 31, 2026

EPS Consensus$-0.05

Range$-0.06 - $-0.04

3 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate Drift

90d ago$-0.04+16.8%

60d ago$-0.04+16.8%

30d ago$-0.04+16.8%

7d ago$-0.04+16.8%

Current$-0.05

Revenue Consensus

$5M

Range$5M - $5M

3 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Oct 31, 2026Oct 26EST	-	$-0.05	$-0.06 - $-0.04	-	-	3	0 1 30d	-
Jul 31, 2026Jul 26EST	-	$-0.05	$-0.06 - $-0.05	-	-	3	0 1 30d	-
Apr 30, 2026Apr 26 Reported Jul 22, 2026Reported Jul 22	$-0.06	$-0.05	$-0.05 - $-0.05	-20.00%	Miss	3	0 1 30d	-50.0%
Jan 31, 2026Jan 26 Reported Mar 12, 2026Reported Mar 12	$-0.06	$-0.04	$-0.04 - $-0.04	-50.00%	Miss	1	No revisions (30d)	+87.0%
Oct 31, 2025Oct 25 Reported Dec 15, 2025Reported Dec 15	$-0.05	$-0.01	$-0.01 - $-0.01	-400.00%	Miss	1	0 1 30d	+16.7%
Jul 31, 2025Jul 25 Reported Sep 15, 2025Reported Sep 15	$-0.09	$-0.04	-	-109.30%	Miss	-	-	+16.4%
Apr 30, 2025Apr 25 Reported Jul 29, 2025Reported Jul 29	$-0.04	$-0.04	-	+0.00%	Beat	-	-	+60.0%
Jan 31, 2025Jan 25 Reported Mar 28, 2025Reported Mar 28	$-0.46	$-0.06	-	-666.67%	Miss	-	-	-475.0%
Oct 31, 2024Oct 24 Reported Dec 10, 2024Reported Dec 10	$-0.06	$-0.07	-	+14.29%	Beat	-	-	+14.3%
Jul 31, 2024Jul 24 Reported Sep 16, 2024Reported Sep 16	$-0.11	N/A	-	N/A	Beat	-	-	-7.6%
Apr 30, 2024Apr 24 Reported Jul 29, 2024Reported Jul 29	$-0.10	$-0.08	-	-25.00%	Miss	-	-	+33.9%
Jan 31, 2024Jan 24 Reported Mar 14, 2024Reported Mar 14	$-0.08	$-0.07	-	-14.29%	Miss	-	-	+42.9%
Oct 31, 2023Oct 23 Reported Dec 14, 2023Reported Dec 14	$-0.07	$-0.10	-	+30.00%	Beat	-	-	+68.2%
Jul 31, 2023Jul 23 Reported Sep 14, 2023Reported Sep 14	$-0.10	$-0.15	-	+33.33%	Beat	-	-	+66.1%
Apr 30, 2023Apr 23 Reported Jul 7, 2023Reported Jul 7	$-0.15	N/A	-	N/A	Beat	-	-	+12.9%
Jan 31, 2023Jan 23 Reported Mar 16, 2023Reported Mar 16	$-0.14	$-0.12	-	-16.67%	Miss	-	-	+10.0%
Oct 31, 2022Oct 22 Reported Dec 15, 2022Reported Dec 15	$-0.22	$-0.14	-	-57.14%	Miss	-	-	-6.8%
Jul 31, 2022Jul 22 Reported Sep 14, 2022Reported Sep 14	$-0.29	N/A	-	N/A	Beat	-	-	-115.6%
Apr 30, 2022Apr 22 Reported Jul 29, 2022Reported Jul 29	$-0.17	N/A	-	N/A	Beat	-	-	+26.8%
Jan 31, 2022Jan 22 Reported Mar 16, 2022Reported Mar 16	$-0.16	N/A	-	N/A	Beat	-	-	-161.8%
Oct 31, 2021Oct 21 Reported Dec 13, 2021Reported Dec 13	$-0.21	N/A	-	N/A	Beat	-	-	-819.6%
Jul 31, 2021Jul 21 Reported Sep 9, 2021Reported Sep 9	$-0.14	N/A	-	N/A	Beat	-	-	-393.5%
Apr 30, 2021Apr 21 Reported Jul 28, 2021Reported Jul 28	$-0.24	N/A	-	N/A	Beat	-	-	-381.9%
Jan 31, 2021Jan 21 Reported Mar 17, 2021Reported Mar 17	$-0.06	N/A	-	N/A	Beat	-	-	-69.7%
Oct 31, 2020Oct 20 Reported Dec 21, 2020Reported Dec 21	$-0.02	N/A	-	N/A	Beat	-	-	+70.4%
Jul 31, 2020Jul 20 Reported Aug 28, 2020Reported Aug 28	$-0.03	N/A	-	N/A	Beat	-	-	+75.1%
Apr 30, 2020Apr 20 Reported Jul 1, 2020Reported Jul 1	$-0.05	N/A	-	N/A	Beat	-	-	+76.8%
Jan 31, 2020Jan 20 Reported Mar 10, 2020Reported Mar 10	$-0.04	N/A	-	N/A	Beat	-	-	+47.3%
Oct 31, 2019Oct 19 Reported Dec 17, 2019Reported Dec 17	$-0.08	N/A	-	N/A	Beat	-	-	+19.7%
Jul 31, 2019Jul 19 Reported Aug 28, 2019Reported Aug 28	$-0.11	N/A	-	N/A	Beat	-	-	-47.5%
Apr 30, 2019Apr 19 Reported Jul 3, 2019Reported Jul 3	$-0.21	N/A	-	N/A	Beat	-	-	-35.3%
Jan 31, 2019Jan 19 Reported Mar 27, 2019Reported Mar 27	$-0.07	N/A	-	N/A	Beat	-	-	+34.5%
Oct 31, 2018Oct 18 Reported Dec 28, 2018Reported Dec 28	$-0.09	N/A	-	N/A	Beat	-	-	-19.3%
Jul 31, 2018Jul 18 Reported Sep 28, 2018Reported Sep 28	$-0.08	N/A	-	N/A	Beat	-	-	+10.3%
Apr 30, 2018Apr 18 Reported Apr 30, 2018Reported Apr 30	$-0.16	N/A	-	N/A	Beat	-	-	-34.6%
Jan 31, 2018Jan 18 Reported Apr 29, 2018Reported Apr 29	$-0.10	N/A	-	N/A	Beat	-	-	+89.5%
Oct 31, 2017Oct 17 Reported Oct 31, 2017Reported Oct 31	$-0.08	N/A	-	N/A	Beat	-	-	-
Jul 31, 2017Jul 17 Reported Jul 31, 2017Reported Jul 31	$-0.08	N/A	-	N/A	Beat	-	-	-
Apr 30, 2017Apr 17 Reported Apr 30, 2017Reported Apr 30	$-0.12	N/A	-	N/A	Beat	-	-	-
Jan 31, 2017Jan 17 Reported Apr 29, 2017Reported Apr 29	$-0.97	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-7.09	EV/EBITDA	-4.68x
Price/FCF	-6.68x	FCF Yield	-14.98%
Profitability
Profit Margin	-89.70%	Operating Margin	-105.20%
ROE	-85.40%	ROIC	-125.09%
Financial Health
Debt/Equity	0.04x	Interest Coverage	N/A
Current Ratio	2.80x	Quick Ratio	2.72x
Trading Statistics
Beta	0.82	Avg Volume	126.88K
52-Week High	$2.99	52-Week Low	$0.99

Technical Indicators Dashboard

Moving Averages

SMA 10$1.39

SMA 20$1.37

SMA 50$1.42

SMA 200$1.53

EMA 10$1.39

EMA 20$1.38

EMA 50$1.41

EMA 200$1.44

MACD

Line: -0.00Signal: -0.01Hist: 0.00

ADX

ADX: 9.6+DI: 15.2-DI: 22.5

Aroon & PSAR

Aroon Up68.0

Aroon Down64.0

PSAR$1.27

Bollinger Bands

Upper Band$1.46

Lower Band$1.28

%B Position1362%(Upper)

Band Width0.34

RSI (14-Day)

Neutral

46.1

Momentum Oscillators

Stoch %K53.3

Stoch %D62.7

Williams %R-64.0

ROC (10d)0.8%

Momentum0.01

CCI (20d)-37.7

MFI (14d)48.1

Volatility Measures

ATR (14d)$0.09(7.0%)

StdDev (20d)0.05

Hist Vol62.0%(High)

Volume Flow

VWAP$1.35

OBV111.5M

AD Line-48.7M

CMF (20d)0.067

Volume Metrics

Avg Vol (20d)126.4K

Vol Ratio0.4x(Low)

VWMA (20d)$1.37

Pivot Points

R3$1.49

R2$1.46

R1$1.43

Pivot Point$1.40

S1$1.37

S2$1.34

S3$1.31

Advanced Oscillators

TSI-0.87

Ultimate Osc55.5

KST-7.03

Financial Data

Quarter	Apr 2026	Jan 2026	Oct 2025	Jul 2025	Apr 2025	Jan 2025	Oct 2024	Jul 2024	Apr 2024	Jan 2024	Oct 2023	Jul 2023
Total Revenue	$4.08M	$4.09M	$4.12M	$3.16M	$6.98M	$6.15M	$2.68M	$2.47M	$6.46M	$6.22M	$6.15M	$5.69M
Cost of Revenue	$1.61M	$1.67M	$1.46M	$1.63M	$2.52M	$2.86M	$1.31M	$1.46M	$3.35M	$3.02M	$3.20M	$2.89M
Gross Profit	$2.47M	$2.42M	$2.66M	$1.53M	$4.46M	$3.29M	$1.37M	$1.01M	$3.11M	$3.20M	$2.95M	$2.79M

Operating Expenses	$6.76M	$6.04M	$5.42M	$5.68M	$5.92M	$6.59M	$5.42M	$5.75M	$6.62M	$6.54M	$5.06M	$2.79M
R&D	$1.56M	$1.19M	$1.23M	$1.05M	$1.09M	$1.06M	$1.01M	$1.49M	$927,000	$1.00M	$835,000	$947,000
SG&A	$5.25M	$4.92M	$3.07M	$3.29M	$3.71M	$3.59M	$2.85M	$3.35M	$4.12M	$4.18M	$3.31M	$3.99M
Operating Income	$-4,291,477	$-3,614,166	$-2,763,000	$-4,153,000	$-1,458,000	$-3,293,000	$-4,054,000	$-4,736,000	$-3,516,000	$-3,340,000	$-2,110,000	$-4,558,000

Interest Income	$17,000	$30,000	$35,000	$5,000	$0	$0	$0	$0	$336,000	$0	$0	$0
Interest Expense	$0	$0	$0	$26,000	$1,944	$3,112	$3,058	$2,027	$4,026	$4,970	$5,062	$5,000
Income Before Tax	$0	$-3,883,704	$-3,194,000	$-4,179,000	$-1,900,000	$-24,535,000	$-4,278,000	$-4,878,000	$-18,822,000	$-3,457,000	$-2,591,000	$-3,831,000
Income Tax Expense	$0	$-17,706	$25,000	$-91,000	$261,000	$-3,014,000	$-731,000	$-666,000	$-777,000	$-778,000	$-182,000	$-415,000

Net Income	N/A	$-3,865,997	$-3,195,000	$-2,959,000	$-2,161,000	$-21,521,000	$-2,553,000	$-3,999,000	$-18,045,000	$-2,679,000	$-2,409,000	$-3,416,000

EBITDA	$-4,055,541	$-3,670,239	$-2,987,000	$-3,237,000	$-988,000	$-22,967,000	$-2,744,000	$-3,480,000	$-17,239,000	$-2,143,000	$-757,000	$-2,272,000
EBIT	$-4,291,477	$-3,883,704	$-3,194,000	$-4,179,000	$-1,901,000	$-24,363,000	$-4,158,000	$-4,876,000	$-18,818,000	$-3,452,000	$-2,110,000	$-3,766,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about HYFT

News

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

AI drug discovery is evolving beyond simply analyzing genetic sequences to understanding the actual function and structure of biological molecules, a more effective approach for identifying viable drug targets. This shift involves integrating AI design with in-house wet labs for continuous experimental validation, attracting significant investment and partnerships from major pharmaceutical companies like Eli Lilly and AstraZeneca. MindWalk Holdings Corp. is highlighted as a smaller company positioning itself in this new wave of "Bio-Native AI" by focusing on functional representation and integrated validation.

The Manila Times•Aug 20, 2026 2:09 AM8/20/26•

Somewhat-Bullish

MindWalk Holdings Corp. (NASDAQ:HYFT) Given Average Recommendation of "Hold" by Analysts

MindWalk Holdings Corp. (NASDAQ:HYFT) has received an average "Hold" recommendation from five research firms, with analysts issuing two sell ratings, two buy ratings, and one strong buy rating. The average 12-month price target is $5.00, significantly higher than its recent share price of $1.33. The company recently missed earnings expectations, reporting a quarterly loss of $0.06 per share on revenue of $3.03 million, with analysts anticipating a full-year loss of $0.21 per share.

MarketBeat•Aug 19, 2026 7:11 AM8/19/26•

Neutral

AI Found an Influenza Target That Survives Viral Mutation

MindWalk Holdings Corp. (Nasdaq: HYFT) has developed an AI platform that identifies functional adjacencies in biology, enabling drug discovery for targets that remain consistent despite viral mutation, such as in influenza. The company showcased its ReefIQ™ technology on AMD Instinct accelerators and is now using its platform to develop its own assets, including a universal influenza program. MindWalk also employs a segregated portfolio structure to fund individual AI-generated assets without diluting parent company shareholders.

GlobeNewswire•Aug 11, 2026 6:11 AM8/11/26•

Somewhat-Bullish

Weekly Recap: Nasdaq compliance, FY26 gains and ReefIQ launch, LensAI deals

MindWalk Holdings Corp. (HYFT) has regained Nasdaq compliance following a September 2025 rebrand and the sale of its Netherlands unit. The company reported a 46% increase in FY2026 revenue to CAD15.6 million, along with a narrower net loss and the launch of new products like ReefIQ and expansion of LensAI. MindWalk also plans to use Advancing AI 2026 for customer briefings in the life sciences sector.

TradingView•Jul 27, 2026 11:41 AM7/27/26•

Bullish

MindWalk Holdings Corp. Revenue Breakdown – NASDAQ:HYFT

MindWalk Holdings Corp. (NASDAQ: HYFT) reported a total revenue of $11.45 million USD last year. The dominant segment contributing to this revenue was Antibody Production Project, generating $11.16 million USD. The majority of the company's revenue, $7.47 million USD, originated from the United States.

TradingView•Jul 27, 2026 11:11 AM7/27/26•

Neutral

Frequently Asked Questions About HYFT

Does HYFT pay dividends?: ImmunoPrecise Antibodies Ltd. (HYFT) does not currently pay a regular dividend.
What is HYFT's market cap?: ImmunoPrecise Antibodies Ltd. (HYFT) has a market capitalization of $62.96M with a current stock price of $1.34.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In